Janux Therapeutics, Inc. (JANX): Price and Financial Metrics


Janux Therapeutics, Inc. (JANX): $22.00

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add JANX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

JANX POWR Grades

  • JANX scores best on the Sentiment dimension, with a Sentiment rank ahead of 75.19% of US stocks.
  • JANX's strongest trending metric is Sentiment; it's been moving up over the last 177 days.
  • JANX ranks lowest in Momentum; there it ranks in the 5th percentile.

JANX Stock Summary

  • JANX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 124.15, JANUX THERAPEUTICS INC has a higher such ratio than 97.83% of stocks in our set.
  • With a year-over-year growth in debt of 10,151.91%, JANUX THERAPEUTICS INC's debt growth rate surpasses 99.58% of about US stocks.
  • Stocks that are quantitatively similar to JANX, based on their financial statements, market capitalization, and price volatility, are INDI, ICVX, MRTX, TSP, and MORF.
  • Visit JANX's SEC page to see the company's official filings. To visit the company's web site, go to www.januxrx.com.

JANX Valuation Summary

  • JANX's price/earnings ratio is -15; this is 166.08% lower than that of the median Healthcare stock.
  • Over the past 20 months, JANX's price/sales ratio has gone down 2392.5.

Below are key valuation metrics over time for JANX.

Stock Date P/S P/B P/E EV/EBIT
JANX 2023-01-20 122.5 2.7 -15.0 -14.3
JANX 2023-01-19 120.4 2.7 -14.7 -14.0
JANX 2023-01-18 121.5 2.7 -14.8 -14.2
JANX 2023-01-17 124.2 2.8 -15.2 -14.5
JANX 2023-01-13 116.1 2.6 -14.2 -13.5
JANX 2023-01-12 98.5 2.2 -12.0 -11.3

JANX Price Target

For more insight on analysts targets of JANX, see our JANX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.00 Average Broker Recommendation 1.38 (Strong Buy)

JANX Stock Price Chart Interactive Chart >

Price chart for JANX

JANX Price/Volume Stats

Current price $22.00 52-week high $23.32
Prev. close $22.00 52-week low $9.39
Day low $21.52 Volume 30,456
Day high $22.21 Avg. volume 217,283
50-day MA $15.27 Dividend yield N/A
200-day MA $13.69 Market Cap 916.59M

Janux Therapeutics, Inc. (JANX) Company Bio


Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.


JANX Latest News Stream


Event/Time News Detail
Loading, please wait...

JANX Latest Social Stream


Loading social stream, please wait...

View Full JANX Social Stream

Latest JANX News From Around the Web

Below are the latest news stories about JANUX THERAPEUTICS INC that investors may wish to consider to help them evaluate JANX as an investment opportunity.

Janux Therapeutics, Inc. (JANX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Janux Therapeutics, Inc. (JANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | January 10, 2023

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

SAN DIEGO, December 27, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that the Company has submitted the investigational new drug (IND) application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for t

Yahoo | December 27, 2022

Janux Therapeutics (NASDAQ:JANX) investors are sitting on a loss of 44% if they invested a year ago

The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...

Yahoo | December 27, 2022

Here's Why Janux Therapeutics, Inc. (JANX) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for Janux Therapeutics, Inc. (JANX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | November 23, 2022

Janux Therapeutics to Present at Upcoming Investor Conferences in November

SAN DIEGO, November 22, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at two upcoming investor conferences and be available for 1x1 meetings. Details of the presentations are as follows:

Yahoo | November 22, 2022

Read More 'JANX' Stories Here

JANX Price Returns

1-mo 82.12%
3-mo 22.77%
6-mo 77.13%
1-year 59.42%
3-year N/A
5-year N/A
YTD 67.05%
2022 -33.25%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.719 seconds.